
LogicBio Therapeutics LOGC
LogicBio Therapeutics Total Shareholders Equity | LOGC
Annual Total Shareholders Equity LogicBio Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 30.7 M | 61.4 M | 42.3 M | 80.2 M | -8.6 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 80.2 M | -8.6 M | 41.2 M |
Quarterly Total Shareholders Equity LogicBio Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 15.7 M | 20.7 M | 24.9 M | 30.7 M | 38.8 M | 44.8 M | 54.2 M | 61.4 M | 22.3 M | 28.2 M | 33.7 M | 42.3 M | 53.2 M | 63.4 M | 72.8 M | 80.2 M | -18.6 M | 80.2 M | 80.2 M | -8.6 M | -8.6 M | -4.93 M | - | -3.25 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 80.2 M | -18.6 M | 35 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Chimerix
CMRX
|
122 M | - | - | $ 756 M | ||
|
AbbVie
ABBV
|
-3.27 B | $ 286.15 | 0.94 % | $ 506 B | ||
|
89bio
ETNB
|
401 M | - | - | $ 1.55 B | ||
|
Harpoon Therapeutics
HARP
|
5.4 M | - | - | $ 763 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
789 M | $ 143.74 | -2.76 % | $ 18.8 B | ||
|
Amgen
AMGN
|
8.66 B | $ 435.4 | -0.21 % | $ 234 B | ||
|
RedHill Biopharma Ltd.
RDHL
|
-4.68 M | $ 0.29 | -11.35 % | $ 3.57 B | ||
|
Seagen
SGEN
|
2.8 B | - | - | $ 42.2 B | ||
|
Baudax Bio
BXRX
|
-24.2 M | - | 0.59 % | $ 63 K | ||
|
ChemoCentryx
CCXI
|
286 M | - | - | $ 3.74 B | ||
|
Avid Bioservices
CDMO
|
60.9 M | - | - | $ 789 M | ||
|
Zosano Pharma Corporation
ZSAN
|
33 M | - | 7.23 % | $ 2.72 M | ||
|
Spectrum Pharmaceuticals
SPPI
|
27.9 M | - | - | $ 189 M | ||
|
Alpine Immune Sciences
ALPN
|
328 M | - | - | $ 2.17 B | ||
|
Berkeley Lights
BLI
|
142 M | - | -7.31 % | $ 87 M | ||
|
Kaleido Biosciences
KLDO
|
10.6 M | - | -3.69 % | $ 12.4 M | ||
|
VBI Vaccines
VBIV
|
7.53 M | - | -50.87 % | $ 1.09 M | ||
|
CTI BioPharma Corp.
CTIC
|
-17.6 M | - | - | $ 1.2 B | ||
|
Decibel Therapeutics
DBTX
|
81.8 M | - | - | $ 123 M | ||
|
Arcutis Biotherapeutics
ARQT
|
189 M | $ 26.35 | -3.02 % | $ 3.35 B | ||
|
IVERIC bio
ISEE
|
535 M | - | - | $ 5.51 B | ||
|
ObsEva SA
OBSV
|
8.35 M | - | -15.52 % | $ 10.5 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
50.3 M | $ 41.53 | -4.86 % | $ 5.88 B | ||
|
Monopar Therapeutics
MNPR
|
138 M | $ 69.02 | -1.81 % | $ 512 M | ||
|
Poseida Therapeutics
PSTX
|
104 M | - | - | $ 857 M | ||
|
Y-mAbs Therapeutics
YMAB
|
92 M | - | - | $ 382 M | ||
|
Satsuma Pharmaceuticals
STSA
|
46.8 M | - | -0.9 % | $ 36.5 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
94.9 M | $ 0.59 | -11.3 % | $ 50.3 M | ||
|
SpringWorks Therapeutics
SWTX
|
481 M | - | - | $ 3.48 B | ||
|
Axon Enterprise
AXON
|
3.24 B | $ 291.02 | -5.2 % | $ 22.7 B | ||
|
Infinity Pharmaceuticals
INFI
|
-19.1 M | - | -46.98 % | $ 3.57 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | ||
|
Evelo Biosciences
EVLO
|
-4.99 M | - | -14.46 % | $ 27.9 M | ||
|
Morphic Holding
MORF
|
697 M | - | - | $ 2.42 B | ||
|
Genocea Biosciences
GNCA
|
27.1 M | - | -15.0 % | $ 3.04 M | ||
|
Biogen
BIIB
|
18.3 B | $ 249.55 | 0.98 % | $ 36.6 B | ||
|
Bristol-Myers Squibb Company
BMY
|
18.5 B | $ 58.74 | 0.69 % | $ 119 B | ||
|
Eiger BioPharmaceuticals
EIGR
|
-14.5 M | - | -9.21 % | $ 2.55 M | ||
|
IGM Biosciences
IGMS
|
48.2 M | - | - | $ 76.9 M | ||
|
Merrimack Pharmaceuticals
MACK
|
18.7 M | - | - | $ 216 M | ||
|
Rubius Therapeutics
RUBY
|
15.1 M | - | -33.55 % | $ 7.81 M | ||
|
Mirati Therapeutics
MRTX
|
997 M | - | - | $ 3.3 B | ||
|
InVivo Therapeutics Holdings Corp.
NVIV
|
15.7 M | - | -37.48 % | $ 476 K | ||
|
Bellicum Pharmaceuticals
BLCM
|
2.02 M | - | -9.72 % | $ 5.89 M | ||
|
Orchard Therapeutics plc
ORTX
|
98.3 M | - | 1.02 % | $ 90.8 M | ||
|
La Jolla Pharmaceutical Company
LJPC
|
-66.7 M | - | - | $ 154 M | ||
|
Oyster Point Pharma
OYST
|
99.5 M | - | - | $ 300 M | ||
|
Intercept Pharmaceuticals
ICPT
|
93.1 M | - | - | $ 643 M | ||
|
Chinook Therapeutics
KDNY
|
442 M | - | - | $ 2.6 B |